Key result
Ortho hs-cTnI yields ~31% myocardial injury incidence in ED patients, exceeding the Abbott hs-cTnI assay.
Why the study?
Differences in patient classification of myocardial injury between hs-cTn assays have largely been attributed to assay design and analytical sensitivity aspects.
Does the OCD hs-cTnI assay yield a different incidence of myocardial injury compared to the Abbott hs-cTnI and OCD cTnI ES assays in emergency department patients?
Observational (n=1,616)
Yes
Does the OCD hs-cTnI assay yield a different incidence of myocardial injury compared to the Abbott hs-cTnI and OCD cTnI ES assays in emergency department patients?
The OCD hs-cTnI assay yields higher rates of biochemical injury and poor reproducibility compared to other troponin assays in emergency department populations, highlighting assay-specific differences in patient classification.
Answers are grounded in this paper and cite their sources.
Troponin assay choice may alter ED myocardial injury classification; leaves open standardization needs and outcome validation.
Differences in patient classification of myocardial injury between high-sensitivity cardiac troponin (hs-cTn) assays have largely been attributed to assay design and analytical sensitivity aspects. Our objective was to compare Ortho Clinical Diagnostics’ (OCD) hs-cTnI assay to OCD’s contemporary/conventional assay (cTnI ES) and another hs-cTnI assay (Abbott hs-cTnI) in samples obtained from different emergency departments (EDs). Two different sample types were evaluated (lithium heparin and ethylenediaminetetraacetic acid (EDTA) plasma) in a non-selected ED population (study 1, n = 469 samples) and in patients for which ED physicians ordered cardiac troponin testing (study 2, n = 1147 samples), from five different EDs. The incidence of injury in study 1 was higher with the OCD hs-cTnI assay (30.9%; 95% CI: 26.9 to 35.2) compared to that of the Abbott hs-cTnI (17.3%; 95% CI: 14.1 to 21.0) and the OCD cTnI ES (15.4%; 95% CI: 12.4 to 18.9) assays, with repeat testing identifying 4.8% (95% CI: 3.0 to 7.5) of the OCD hs-cTnI results with poor reproducibility. In study 2, 4.6% (95% CI: 3.5 to 6.0) of the results were not reported for the OCD hs-cTnI assay (i.e., poor reproducibility) with 12.7% (95%CI: 8.7 to 17.8) of the OCD hs-cTnI results positive for injury being negative for injury with the Abbott hs-cTnI assay. In summary, the OCD hs-cTnI assay yields higher rates of biochemical injury with a higher rate of poor reproducible results in different ED populations.
No takes yet. Share an insight, caveat, or question.
Kavsak et al. (2021) conducted an observational in Myocardial injury (n=1,616). Ortho Clinical Diagnostics hs-cTnI assay vs. Abbott hs-cTnI and OCD cTnI ES assays was evaluated on Incidence of myocardial injury. The Ortho Clinical Diagnostics hs-cTnI assay yielded a higher incidence of myocardial injury compared to the Abbott hs-cTnI and OCD cTnI ES assays in ED patients.
Synapse has enriched 10 related papers. Consider them for comparative context: